Investors push up Neurochem stock on data review

Shares of Neurochem jumped this morning when the company announced plans to update its data on its Alzheimer's therapy Alzhemed. Neurochem's stock took off on a roller coaster ride last April as investors fretted over fears that the drug data was not good enough to satisfy regulators. The update is expected from its lead investigator at a conference later today, but the company has cautioned that no conclusions can yet be reached on the therapy.

- see the release
- read the AP report on the review

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.